Synthesis of aryl phosphates based on pyrimidine and triazine scaffolds

European Journal of Medicinal Chemistry

Volumn 45, Issue 1, 2010, Pages 244-255

  Courme, Caroline ^a,b   Gresh, Nohad ^c,d   Vidal, Michel ^c,d   Lenoir, Christine ^c,d   Garbay, Christiane ^c,d   Florent, Jean Claude ^a,b   Bertounesque, Emmanuel ^a,b  

^a CNRS   (France)

^b INSTITUT CURIE   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Laboratoire de Pharmacochimie   (France)

Author keywords

1,3,5 Triazines; 2 Aminopyrimidines; Aryl phosphates; De novo design; Grb2 SH2 domain; Heck reaction; Protein tyrosine kinases; Suzuki Miyaura reaction

Indexed keywords

1 (4 CYANOPHENYL)GUANIDINE; 2 [4 CHLORO 6 (4 HYDROXYPHENYLAMINO) 1,3,5 TRIAZIN 2 YLAMINO]ACETAMIDE; 2 [4 [2 (4 PHOSPHORYLOXYPHENOXY)PHENYL] 6 (4 PHOSPHORYLOXYPHENYLAMINO) 1,3,5 TRIAZIN 2 YLAMINO]ACETAMIDE; 2 [4 [3 (4 PHOSPHORYLOXYPHENOXY)PHENYL] 6 (4 PHOSPHORYLOXYPHENYLAMINO) 1,3,5 TRIAZIN 2 YLAMINO]ACETAMIDE; 4 [3 (4 BENZYLOXYPHENOXY)PHENYL]BUT 3 EN 2 ONE; 4 [3 [2 [4 (2H TETRAZOL 5 YL)PHENYLAMINO] 6 METHYLPYRIMIDIN 4 YL]PHENOXY]PHENYL DIHYDROGEN PHOSPHATE; ACETAMIDE DERIVATIVE; ALKANONE; GUANIDINE; PHOSPHATE; PYRIMIDINE; TRIAZINE; UNCLASSIFIED DRUG;

ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; MOLECULAR MODEL; SUBSTITUTION REACTION; SUZUKI REACTION;

EID: 72049092280     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2009.10.003     Document Type: Article

References (95)

1. For a review of bioactive pyrimidines, see:. Fabbro D., Ruetz S., Buchdunger E., Cowan-Jacob S.W., Fendrich G., Liebetanz J., Mestan J., O'Reilly T., Traxler P., Chaudhuri B., Fretz H., Zimmerman J., Meyer T., Caravatti G., Furet P., and Manley P.W. Pharmacol. Ther. 93 (2002) 79-98
2. Zimmermann J., Buchdunger E., Mett H., Meyer T., and Lydon N.B. Bioorg. Med. Chem. Lett. 7 (1997) 187-192
3. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., Cornelissen J.J., Fischer T., Hochhaus A., Hughes T., Lechner K., Nielsen J.L., Rousselot P., Reiffers J., Saglio G., Shepherd J., Simonsson B., Gratwohl A., Goldman J.M., Kantarjian H., Taylor K., Verhoef G., Bolton A.E., Capdeville R., and Druker B.J. N. Engl. J. Med. 348 (2003) 994-1004
4. Wang S., Wood G., Meades C., Griffiths G., Midgley C., McNae I., McInnes C., Anderson S., Jackson W., Mezna M., Yuill R., Walkinshaw M., and Fischer P. Bioorg. Med. Chem. Lett. 14 (2004) 4237-4240
5. Chu X.-J., DePinto W., Bartkovitz D., So S.-S., Vu B.T., Packman K., Lukacs C., Ding Q., Jiang N., Wang K., Goelzer P., Yin X., Smith M.A., Higgins B.X., Chen Y., Xiang Q., Moliterni J., Kaplan G., Graves B., Lovey A., and Fotouhi N. J. Med. Chem. 49 (2006) 6549-6560
6. Lücking U., Siemeister G., Schäfer M., Briem H., Krüger M., Lienau P., and Jautelat R. Chem. Med. Chem. 2 (2007) 63-77
7. Martin M.W., Newcomb J., Nunes J.J., McGowan D.C., Armistead D.M., Boucher C., Buchanan J.L., Buckner W., Chai L., Elbaum D., Epstein L.F., Faust T., Flynn S., Gallant P., Gore A., Gu Y., Hsieh F., Huang X., Lee J.H., Metz D., Middleton S., Mohn D., Morgenstern K., Morrison M.J., Novak P.M., Oliveira-dos-Santos A., Powers D., Rose P., Schneider S., Sell S., Tudor Y., Turci S.M., Welcher A.A., White R.D., Zack D., Zhao H., Zhu L., Zhu X., Ghiron C., Amouzegh P., Ermann M., Jenkins J., Johnston D., Napier S., and Power E. J. Med. Chem. 49 (2006) 4981-4991
8. For a review on applications of cyanuric chloride in organic synthesis, see:. Blotny G. Tetrahedron 62 (2006) 9507-9522 and references 1-6 cited therein
9. Moon H.-S., Jacobson E.M., Khersonsky S.M., Luzung M.R., Walsh D.P., Xiong W., Lee J.W., Parikh P.B., Lam J.C., Kang T.-W., Rosania G.R., Schier A.F., and Chang Y.-T. J. Am. Chem. Soc. 124 (2002) 11608-11609
10. Menicagli R., Samaritani S., Signore G., Vaglini F., and Dalla Via L. J. Med. Chem. 47 (2004) 4649-4652
11. Mandal S., Bérubé G., Asselin E., Mohammad I., Richardson V.J., Gupta A., Pramanik S.K., Williams A.L., and Mandal S.K. Bioorg. Med. Chem. Lett. 17 (2007) 4955-4960
12. Baindur N., Chadha N., Brandt B.M., Asgari D., Patch R.J., Schalk-HiHi C., Carver T.E., Petrounia I.P., Baumann C.A., Ott H., Manthey C., Springer B.A., and Player M.R. J. Med. Chem. 48 (2005) 1717-1720
13. Hodous B.L., Geuns-Meyer S.D., Hughes P.E., Albrecht B.K., Bellon S., Bready J., Caenepeel S., Cee V.J., Chaffee S.C., Coxon A., Emery M., Fretland J., Gallant P., Gu Y., Hoffman D., Johnson R.E., Kendall R., Kim J.L., Long A.M., Morrison M., Olivieri P.R., Patel V.F., Polverino A., Rose P., Tempest P., Wang L., Whittington D.A., and Zhao H. J. Med. Chem. 50 (2007) 611-626
14. Agarwal A., Srivastava K., Puri S.K., and Chauhan P.M.S. Bioorg. Med. Chem. Lett. 15 (2005) 531-533
15. Baliani A., Bueno G.J., Stewart M.L., Yardley V., Brun R., Barrett M.P., and Gilbert I.H. J. Med. Chem. 48 (2005) 5570-5579
16. Huang W., Zheng W., Urban D.J., Inglese J., Sidransky E., Austin C.P., and Thomas C.J. Bioorg. Med. Chem. Lett. 17 (2007) 5783-5789
17. For reviews, see:. Fretz H., Furet P., García Echeverría C., Rahuel J., and Schoepfer J. Curr. Pharm. Des. 6 (2000) 1777-1796
18. Vu C.B. Curr. Med. Chem. 7 (2000) 1081-1100
19. Vidal M., Gigoux V., and Garbay C. Crit. Rev. Oncol. Hematol. 40 (2001) 175-186
20. Shakespeare W.C. Curr. Opin. Chem. Biol. 5 (2001) 409-415
21. Burke Jr. T.R., and Lee K. Acc. Chem. Res. 36 (2003) 426-433
22. Machida K., and Mayer B.J. Biochim. Biophys. Acta 1747 (2005) 1-25
23. For the crystal structure of the mammalian Grb2 adaptor which is deposited in the Protein Data Bank under the accession code 1GRI, see:. Maignan S., Guilloteau J.P., Fromage N., Arnoux B., Becquart J., and Ducruix A. Science 268 (1996) 291-293
24. Courme C., Gillon S., Gresh N., Vidal M., Garbay C., Florent J.-C., and Bertounesque E. Tetrahedron Lett. 49 (2008) 4542-4545
25. For molecular modeling of ligand 1 binding mode to Grb2 SH2, see:. Liu W.-Q., Vidal M., Gresh N., Roques B.P., and Garbay C. J. Med. Chem. 42 (1999) 3737-3741
26. For the X-ray crystallographic data of the ligand 1 binding to Grb2 SH2, see:. Nioche P., Liu W.-Q., Boutin I., Charbonnier F., Latreille M.-T., Vidal M., Roques B.P., Garbay C., and Ducruix A. J. Mol. Biol. 315 (2002) 1167-1177
27. Liu W.-Q., Vidal M., Olszowy C., Million E., Lenoir C., Dhotel H., and Garbay C. J. Med. Chem. 47 (2004) 1223-1233
28. Benfield A.P., Teresk M.G., Plake H.R., DeLorbe J.E., Millspaugh L.E., and Martin S.F. Angew. Chem. 118 (2006) 6984-6989
29. Benfield A.P., Teresk M.G., Plake H.R., Delorbe J.E., Millspaugh L.E., and Martin S.F. Angew. Chem. Int. Ed. Engl. 45 (2006) 6830-6835
30. X ray crystallographic data are deposited in the Protein Data Bank under the accession codes 2HUW and 2HUY. This latter was obseleted on 2008-08-12 and superceded by 3C7I.
31. For reviews on tetrazoles as carboxylic acid isosteres, see:. Patani G.A., and LaVoie E.J. Chem. Rev. 96 (1996) 3147-3176
32. Herr R.J. Bioorg. Med. Chem. 10 (2002) 3379-3393
33. A Scifinder search on the triazine scaffold incorporating a bis-aryl phosphate exclusively identified two patents, on triazine dyes, see: B.L. McConnell, R. Thornton, L.A. Graham, U.S. US 4091004 19780523; 1978 and ref. [34].
34. K. Sato, H. Tanaka, Jpn. Kokai Tokkyo Koho. JP 04117369 A 19920417 Heisei. CAN 117:152766 AN 1992:552766; 1992.
35. For example, see: R.T. Timmer, C.W. Alexander, S. Pillarisetti, U. Saxena, K.R. Yeleswarapu, M. Pal, J.T. Reddy, V.V.R.M.K. Reddy, B.S. Sridevi, P.R. Kumar, G.O. Reddy, PCT Int. Appl. WO 2004026844; 2004.
36. For compound 8, see: A Scifinder search exclusively identified three patents. P. Furet, P. Imbach, T.M. Ramsey, A. Schlapbach, D. Scholz, G. Caravatti, PCT Int. Appl. WO 2004005282; 2004.
37. For compound 9, see: S. Jones, B. Westwood, M. Thomas, J. McLachlan, K. Duncan, F. Scaerou, D. Zheleva, PCT Int. Appl. WO 2007042784; 2007.
38. For compound 10, see: C.F. Claiborne, L.J. Payne, R.J. Boyce, T.B. Sells, S.G. Stroud, S. Travers, T.J. Vos, G.S. Weatherhead, U.S. Pat. Appl. Publ. US 20050256102; 2005.
39. Diels O. Ber. Dtsch. Chem. Ges. 32 (1899) 691-702
40. Koopman H., and Daams J. Recl. Trav. Chim. Pays-Bas 77 (1958) 235-240
41. Goi M. Yuki Gosei Kagaku Kyokaishi 18 (1960) 327-331
42. Goi M. Yuki Gosei Kagaku Kyokaishi 18 (1960) 332-336
43. Katritzky A.R., Oniciu D.C., Ghiviriga I., and Barcock R.A. J. Chem. Soc. Perkin Trans. 2 (1995) 785-792
44. de Hoog P., Gamez P., Driessen W.L., and Reedijk J. Tetrahedron Lett. 43 (2002) 6783-6786
45. Leftheris K., Ahmed G., Chan R., Dyckman A.J., Hussain Z., Ho K., Hynes Jr. J., Letourneau J., Li W., Lin S., Metzger A., Moriarty K.J., Riviello C., Shimshock Y., Wen J., Wityak J., Wrobleski S.T., Wu H., Wu J., Desai M., Gillooly K.M., Lin T.H., Loo D., McIntyre K.W., Pitt S., Shen D.R., Shuster D.J., Zhang R., Diller D., Doweyko A., Sack J., Baldwin J., Barrish J., Dodd J., Henderson I., Kanner S., Schieven G.L., and Webb M. J. Med. Chem. 47 (2005) 6283-6291
46. Baliani A., Bueno G.J., Stewart M.L., Yardley V., Brun R., Barrett M.P., and Gilbert I.H. J. Med. Chem. 48 (2005) 5570-5579
47. Sandler S.R. J. Org. Chem. 35 (1970) 3967-3968 and references cited therein
48. Menicagli R., Malanga C., and Peluso P. Synth. Commun. 24 (1994) 2153-2158
49. Koopman H., Uhlenbroek J.H., Haeck H.H., Daams J., and Koopmans M.J. Recl. Trav. Chim. Pays-Bas 78 (1959) 967-978
50. Bork J.T., Lee J.W., Khersonsky S.M., Moon H.-S., and Chang Y.-T. Org. Lett. 5 (2003) 117-120
51. For the preparation of 2,4,6-tricyano-1,3,5-triazine (TCT), see: G. Beck, United States Patent 5086172; 1992.
52. Yamanaka H., Ohba S., and Konno S. Heterocycles 26 (1987) 2853-2856
53. Faust R., and Gobelt B. Tetrahedron Lett. 38 (1997) 8017-8020
54. Samaritani S., Signore G., Malanga C., and Menicagli R. Tetrahedron 61 (2005) 4475-4483
55. To the best of our knowledge, only one report mentioned the monocoupling reaction of organoboronic acids with 2,4,6-trichloro-1,3,5-triazine, see:. Tan J.-Q., Chang J.-H., and Deng M.-Z. Chin. J. Chem. 22 (2004) 941-944
56. Janietz D., and Bauer M. Synthesis (1993) 33-34
57. Bork J.T., Lee J.W., and Chang Y.-T. Tetrahedron Lett. 44 (2003) 6141-6144
58. Cooke G., Augier de Cremiers H., Rotello V.M., Tarbit B., and Vanderstraeten P.E. Tetrahedron 57 (2001) 2787-2789
59. Montalbetti C.A.G.N., Coulter T.S., Uddin M.K., Reignier S.G., Magaraci F., Granäs C., Krog-Jensen C., and Felding J. Tetrahedron Lett. 47 (2006) 5973-5975
60. Kuo G.-H., DeAngelis A., Stuart E., Wang A., Zhang Y., Connolly P.J., Chen X., Gruninger R.H., Rugg C., Fuentes-Pesquera A., Middleton S.A., Jolliffe L., and Murray W.V. J. Med. Chem. 48 (2005) 4535-4546
61. Menicagli R., Samaritani S., and Zucchelli V. Tetrahedron 56 (2000) 9705-9711 and references cited therein
62. Yang G.-S., Xie X.-J., Zhao G., and Ding Y. J. Fluorine Chem. 98 (1999) 159-162
63. Robinson R.P., Laird E.R.J., Blake F., Bordner J., Donahue K.M., Lopresti-Morrow L.L., Mitchell P.G., Reese M.R., Reeves L.M., Stam E.J., and Yocum S.A. J. Med. Chem. 43 (2000) 2293-2296
64. Juneja R.K., Robinson K.D., Johnson C.P., and Atwood J.L. J. Am. Chem. Soc. 115 (1993) 3818-3819
65. Hajduk P.J., Dinges J., Miknis G.F., Merlock M., Middleton T., Kempf D.J., Egan D.A., Walter K.A., Robins T.S., Shuker S.B., Holzman T.F., and Fesik S.W. J. Med. Chem. 40 (1997) 3144-3150
66. Daines R.A., Sham K.K.C., Taggart J.J., Kingsbury W.D., Chan J., Breen A., Disa J., and Aiyar N. Bioorg. Med. Chem. Lett. 20 (1997) 2673-2676
67. Koelbel M., Beyersdorff T., Tschierske C., Diele S., and Kain J. Chem. Eur. J. 20 (2000) 3821-3837
68. Wu T.Y.H., Ding S., Gray N.S., and Schultz P.G. Org. Lett. 3 (2001) 3827-3830
69. Steffensen M.B., and Simanek E.E. Org. Lett. 5 (2003) 2359-2361
70. For a previous work on the displacement of aryl fluorides with hydroquinone, see:. Marcune B.F., Hillier M.C., Marcoux J.-F., and Humphrey G.R. Tetrahedron Lett. 46 (2005) 7823-7826
71. Szajnman S.H., Yan W., Bailey B.N., Docampo R., Elhalem E., and Rodriguez J.B. J. Med. Chem. 43 (2000) 1826-1840
72. 3): m/z 417, 419, 421], resulting from the reaction of hydroquinone as an aryloxide C-nucleophile, and an unidentified compound.
73. For an alternative method (i.e., a copper-catalyzed arylboronic acid-heteroatom coupling) to access such a boronic acid, see:. Pennington T.E., Kardiman C., and Hutton C.A. Tetrahedron Lett. 45 (2004) 6657-6660
74. Silverberg L.J., Dillon J.L., and Vemishetti P. Tetrahedron Lett. 37 (1996) 771-774
75. For an adaptation of the phosphorylation procedure described by Silverberg et al. [74] for solid-phase synthesis, see:. Deprez P., Mandine E., Gofflo D., Meunier S., and Lesuisse D. Bioorg. Med. Chem. Lett. 12 (2002) 1295-1298
76. Grzyska P.K., Czyryca P.G., Purcell J., and Hengge A.C. J. Am. Chem. Soc. 2125 (2003) 13106-13111 and references cited therein
77. Cocuzza A.J., Hobbs F.W., Arnold C.R., Chidester D.R., Yarem J.A., Culp S., Fitzgerald L., and Gilligan P.J. Bioorg. Med. Chem. Lett. 9 (1999) 1057-1062
78. Strekowski L., Harden D.B., Grubb III W.B., Patterson S.E., Czarny A., Mokrosz M., Cegla M.T., and Wydra R. J. Heterocycl. Chem. 27 (1990) 1393-1400
79. Bursavich M.G., Lombardi S., and Gilbert A.M. Org. Lett. 7 (2005) 4113-4116
80. Cocuzza A.J., Chidester D.R., Culp S., Fitzgerald L., and Gilligan P.J. Bioorg. Med. Chem. Lett. 9 (1999) 1063-1066
81. Wendelin W., and Schermanz K. J. Heterocycl. Chem. 21 (1984) 65-69 and references cited therein
82. Delia T.J., Schomaker J.M., and Kalinda A.S. J. Heterocycl. Chem. 43 (2006) 127-131
83. For an example of the Heck reaction of halogeno-diphenyl ethers with ethyl acrylate, see:. Orr G.F., Musso D.L., Kelley J.L., Joyner S.S., Davis S.T., and Baccanari D.P. J. Med. Chem. 40 (1997) 1179-1185
84. Xu X., Fakha G., and Sinou D. Tetrahedron 58 (2002) 7539-7544
85. For the thermal polymerization of a vinyl ketone during the Heck reaction, see:. Uchiro H., Nagasawa K., Aiba Y., and Kobayashi S. Tetrahedron Lett. 41 (2000) 4165-4168
86. For the value of α,β-unsaturated ketones as key intermediates for the synthesis of pyrimidines on the solid phase, see:. Marzinzik A.L., and Felder E.R.J. Org. Chem. 63 (1998) 723-727
87. Bauer V.J., and Safir S.R. J. Med. Chem. 9 (1966) 244-246
88. Amantini D., Beleggia R., Fringuelli F., Pizzo F., and Vaccaro L. J. Org. Chem. 69 (2004) 2896-2898
89. Liu W.-Q., Vidal M., Olszowy C., Million E., Lenoir C., Dhotel H., and Garbay C. J. Med. Chem. 47 (2004) 1223-1233
90. 50 = 174 μM): see, XXth International Symposium on Medicinal Chemistry, August 31- September 4, 2008, Vienna, Austria. Poster Presentation P527 Development of non-peptide inhibitors of Her2-Grb2 interaction using molecular modeling and NMR spectroscopy. M.L. López-Rodriguez, S. Ortega-Gutiérrez, B. Benhamú, Á.L. Orcajo, P. Serrano, A.Viso, I.R. Torrecillas, M. Campillo, L. Pardo, K. Wüthrich.
91. See Supporting information.
92. Low-temperature molecular dynamics (300 steps of 5 picoseconds each, T = 100 K, ε = 4.) were done with the Discover module and the Cff91 force-field of the Insight II package (Accelrys, Inc). We resorted to the crystal structure of the complex of 1 with Grb2-SH2 to dock 1 and all non-peptidic compounds in the binding site.
93. Chen Y.T., and Seto C.T. Bioorg. Med. Chem. 12 (2004) 3289-3298
94. Xie J., and Seto C.T. Bioorg. Med. Chem. 15 (2007) 458-473
95. Combs A.P., Yue E.W., Bower M., Ala P.J., Wayland B., Douty B., Takvorian A., Polam P., Wasserman Z., Zhu W., Crawley M.L., Pruitt J., Sparks R., Glass B., Modi D., McLaughlin E., Bostrom L., Li M., Galya L., Blom K., Hillman M., Gonneville L., Reid B.R., Wei M., Becker-Pasha M., Klabe R., Huber R., Li Y., Hollis G., Burn T.C., Wynn R., Liu P., and Metcalf B. J. Med. Chem. 48 (2005) 6544-6548